Top Markets
Coin of the day
Medigene AG Medigene AG

Medigene AG

MDG1
株式のランク #35468
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
株価
$0.14942078
最終同期: 2025-05-15
時価総額
$3.86M
変化(1日)
0.10%
変化(1年)
0.00%
DE
取引 Medigene AG (MDG1)

カテゴリー

Medigene AG(MDG1)のP/S比率
August 2026 時点のP/S比率 TTM: 0.33
Medigene AG の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0.33 です。2022 年末時点でのP/S比率は 1.58 でした。
Medigene AG の P/S 比率の履歴(2004 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 0.33 -94.44%
2023 5.86 270.74%
2022 1.58 -76.40%
2021 6.70 -37.67%
2020 10.75 15.55%
2019 9.30 -81.25%
2018 49.61 -30.09%
2017 70.97 -38.41%
2016 115.23 29.31%
2015 89.11 1,204.14%
2014 6.83 -18.93%
2013 8.43 -29.80%
2012 12.01 -23.25%
2011 15.64 -52.41%
2010 32.87 915.33%
2009 3.24 -25.83%
2008 4.36 -43.78%
2007 7.76 51.85%
2006 5.11 -35.56%
2005 7.93 -16.62%
2004 9.52 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差
10.17 3,018.00%
US
10.13 3,006.19%
NL
- -
CH
- -
KR
4.74 1,354.31%
BE